Zai Lab Limited (NASDAQ:ZLAB) Insider Sells $115,230.00 in Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 3,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $38.41, for a total transaction of $115,230.00. Following the transaction, the insider now owns 30,834 shares in the company, valued at $1,184,333.94. The trade was a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rafael Amado also recently made the following trade(s):

• On Tuesday, December 31st, Rafael Amado sold 7,583 shares of Zai Lab stock. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24.

Zai Lab Stock Down 6.0 %

Shares of NASDAQ ZLAB opened at $35.09 on Friday. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $39.61. The firm has a market cap of $3.85 billion, a PE ratio of -12.67 and a beta of 1.08. The business has a fifty day simple moving average of $30.70 and a two-hundred day simple moving average of $27.70.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. On average, research analysts expect that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZLAB. JPMorgan Chase & Co. raised their price target on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, March 13th. Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a research report on Tuesday, March 4th. Scotiabank initiated coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price target on the stock. Finally, Bank of America reiterated a “neutral” rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently modified their holdings of ZLAB. GF Fund Management CO. LTD. bought a new position in Zai Lab in the fourth quarter worth approximately $29,000. Public Employees Retirement System of Ohio raised its position in shares of Zai Lab by 20.8% in the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after acquiring an additional 3,179 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after purchasing an additional 1,200 shares during the last quarter. Woodline Partners LP boosted its position in Zai Lab by 9.4% during the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock valued at $46,089,000 after purchasing an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Zai Lab in the fourth quarter valued at about $7,857,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.